EXACT SCIENCES CORP

exactsciences.com

No Longer Reporting

The company has not filed an annual or quarterly report since its FY2025 10-K, filed Feb 13, 2026. Its latest SEC filing is a 15-12G from Apr 2, 2026.

The sections below describe the company as of the FY2025 annual report.

What Did They Do?

Sells cancer screening tests and tumor-based tests that help guide treatment to patients and health care professionals.

How Did They Make Money?

Patients’ tests are paid for through insurance benefits and payer reimbursement; bills generally go out after the test result is released to the ordering provider, while self-pay patients and some lab-agreement customers pay before testing begins.

FY2025 revenue

Who Were Their Customers?

Patients are the primary customers, with tests ordered by health care providers. International distributor partners also help make the company’s lab testing available to patients.

Did Revenues Turn Into Profits?

Not on paper. It lost $207.9M in FY2025, but brought in more cash than it spent: $356.8M of free cash flow.

Operating income, FY2025

−6% of revenue

▼ −80% (Loss) vs FY2024 (−$1B, −38%)

Net income, FY2025

−6% of revenue

▼ −80% (Loss) vs FY2024 (−$1B, −37%)

Free cash flow, FY2025

11% of revenue

▲ +379% vs FY2024 ($74.5M, 3%)

How Were They Changing?

Since the FY2025 annual report

Mar 23, 2026 Exact Sciences became a wholly owned Abbott subsidiary The merger closed, with Exact surviving as Abbott’s direct, wholly owned subsidiary; eligible shares converted into cash consideration.

Grew. Revenue grew 84% in 4 years, from $1.8B in FY2021 to $3.2B in FY2025, about 16% a year.

Who Did They Compete With?

Competes with Geneoscopy, Mainz Biomed, Prescient Metabiomics, Guardant Health, Freenome, GRAIL, Natera, Caris Life Sciences, Ambry Genetics, Tempus AI, Myriad Genetics, Color Health, GeneDx, Illumina, Variantyx, 3billion, LabCorp, Quest Diagnostics, Agendia, and Veracyte

Comments